Phaseline

Companies › Rege Nephro

Rege Nephro: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tamibarotene
Retinoic acid receptor beta agonist; Retinoic acid receptor alpha agonist
RARB, RARAPhase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD); HFpEF - Heart Failure With Preserved Ejection Fraction–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06289998TamibarotenePhase 2Autosomal Dominant Polycystic Kidney Disease (ADPKD)GenitourinaryDec 2025
NCT07855692TamibarotenePhase 2HFpEF - Heart Failure With Preserved Ejection FractionCardiovascularMay 2029

Targets

RARB (1) RARA (1)

Companies with the same targets

IR INNOVATE RESEARCH PRIVATE HighField Biopharmaceuticals

Companies built like this

Noorik Biopharmaceuticals Tectonic Operating Company CuraSen Therapeutics Neurimmune Kira Pharmacenticals (US)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.